Search
Atovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: Malarone 250 mg/100 mg Filmtabletten, MALARONE (250/100 MG TABLETS)Products: ATOVAQUONE E PROGUANILE SANDOZElbasvir
go.drugbank.com/drugs/DB11574Approved[A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication … grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100%
Mixtures: ZEPATIER 50 MG/100 MG FİLM KAPLI TABLET, 28 ADETDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Mixtures: TRODERM 10 MG/G+1 MG/G KREM ,15 G, TİNAGEN 1 MG+10 MG/1 G DERİ KREMİ, 15 GProducts: NERIFORTE POMAD, 10 G, TEMETEX %01 KREM, 10 GSipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalFood and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS, D-ARTEPPRimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Categories: M2 Protein Inhibitors, Influenza A M2 Protein InhibitorLevorphanol
go.drugbank.com/drugs/DB00854ApprovedA narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.
Bempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous
Polihexanide
go.drugbank.com/drugs/DB12277ApprovedInvestigational[A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]
Categories: Compounds used in a research, industrial, or household settingPemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.